At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 110 enrolled
Drug / intervention
Bydureonbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 4 clinical trial evaluating Bydureon for Type 2 Diabetes Mellitus. Completed, enrolled 110 participants across 15 sites.
Detailed Summary
As current study is conducted to provide additional information regarding safety and efficacy Bydureon, exenatide once weekly for injectable suspension, in the Korean population open label, non-comparative, multi-centre design is used.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartJan 2016
Primary CompletionDec 2016
TodayJul 2026
First PostedAug 26, 2015
Enrollment StartJan 28, 2016
Primary CompletionDec 7, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 10.8 years ago
Interventions
Bydureonbiological
exenatide once weekly